Male, n (%)
|
94 (94.9)
|
59 (78.7)
|
24 (52.2)
|
< 0.001
|
127 (96.2)
|
40 (66.7)
|
14 (50.0)
|
< 0.001
|
Age, years
|
57.9 ± 11.7
|
67.9 ± 10.7
|
73.7 ± 9.3
|
< 0.001
|
61.3 ± 12.1
|
68.0 ± 9.3
|
74.6 ± 12.4
|
< 0.001
|
Body mass index, kg/m2
|
25.4 ± 2.5
|
25.5 ± 2.6
|
25.9 ± 2.1
|
0.605
|
25.0 ± 2.5
|
25.0 ± 1.9
|
25.7 ± 2.4
|
0.294
|
Hypertension, n (%)
|
102 (77.3)
|
37 (61.7)
|
7 (25.0)
|
< 0.001
|
91 (91.9)
|
42 (56.0)
|
11 (23.9)
|
< 0.001
|
History of dyslipidemia, n (%)
|
23 (17.4)
|
25 (41.7)
|
14 (50.0)
|
< 0.001
|
2 (2.0)
|
20 (26.7)
|
26 (56.5)
|
< 0.001
|
Smoking, n (%)
|
27 (27.3)
|
26 (34.7)
|
21 (45.7)
|
0.090
|
43 (32.6)
|
18 (30.0)
|
15 (53.6)
|
0.072
|
History of MI, n (%)
|
19 (19.2)
|
16 (21.3)
|
19 (41.3)
|
0.012
|
19 (14.4)
|
12 (20.0)
|
10 (35.7)
|
0.030
|
Severity of CAD, n (%)
|
< 0.001
| | | |
< 0.001
|
1-vessel
|
39 (39.4)
|
2 (2.7)
|
0 (0.0)
|
< 0.001
|
51 (38.6)
|
5 (8.3)
|
5 (17.9)
|
< 0.001
|
2-vessel
|
35 (35.4)
|
21 (28.0)
|
17 (37.0)
|
0.493
|
55 (41.7)
|
17 (28.3)
|
7 (25.0)
|
0.089
|
3-vessel
|
25 (25.2)
|
52 (69.3)
|
29 (63.0)
|
< 0.001
|
26 (19.7)
|
38 (63.3)
|
16 (57.1)
|
< 0.001
|
Multivessel disease
|
60 (60.6)
|
73 (97.3)
|
46 (100.0)
|
< 0.001
|
81 (61.4)
|
55 (91.7)
|
23 (82.1)
|
< 0.001
|
Stenosis of PCDA, %
|
37.6 ± 8.5
|
58.9 ± 5.3
|
83.4 ± 8.5
|
< 0.001
|
33.5 ± 10.5
|
58.9 ± 5.4
|
82.6 ± 8.4
|
< 0.001
|
Fast blood glucose, mmol/L
|
6.3 ± 1.9
|
6.9 ± 2.2
|
6.5 ± 2.7
|
0.214
|
5.0 ± 0.7
|
4.7 ± 0.7
|
5.3 ± 0.6
|
< 0.001
|
HbA1c, %
|
7.2 ± 1.2
|
7.4 ± 1.5
|
7.1 ± 1.3
|
0.555
|
5.7 ± 0.4
|
5.7 ± 0.4
|
5.8 ± 0.4
|
0.980
|
Triglyceride, mmol/L
|
1.55 ± 0.72
|
1.62 ± 0.63
|
1.68 ± 0.81
|
0.538
|
1.42 ± 0.71
|
1.45 ± 0.83
|
1.60 ± 0.71
|
0.521
|
Total cholesterol, mmol/L
|
3.75 ± 1.04
|
4.11 ± 1.12
|
4.29 ± 1.04
|
0.009
|
4.11 ± 1.34
|
3.89 ± 1.45
|
4.08 ± 0.88
|
0.571
|
HDL cholesterol, mmol/L
|
0.94 ± 0.20
|
0.99 ± 0.28
|
0.99 ± 0.16
|
0.312
|
1.01 ± 0.27
|
0.96 ± 0.19
|
1.00 ± 0.34
|
0.469
|
LDL cholesterol, mmol/L
|
2.23 ± 0.90
|
2.47 ± 0.93
|
2.71 ± 0.87
|
0.010
|
2.49 ± 1.05
|
2.45 ± 1.11
|
2.40 ± 0.84
|
0.891
|
Serum creatinine, μmol/L
|
85 ± 21
|
90 ± 30
|
110 ± 32
|
< 0.001
|
77 ± 14
|
94 ± 27
|
102 ± 29
|
< 0.001
|
Uric acid, μmol/L
|
322 ± 79
|
315 ± 61
|
331 ± 76
|
0.515
|
337 ± 72
|
319 ± 96
|
339 ± 69
|
0.309
|
GFR, mL/min/1.73 m2
|
86.8 ± 18.5
|
75.5 ± 24.9
|
55.9 ± 20.6
|
< 0.001
|
90.3 ± 15.8
|
70.7 ± 20.2
|
59.6 ± 21.8
|
< 0.001
|
hsCRP, mg/L
|
1.58 (0.66–3.32)
|
2.46 (1.21–7.55)
|
4.23 (1.44–17.15)
|
0.031
|
0.97 (0.25–3.13)
|
1.20 (0.27–10.35)
|
2.66 (0.42–25.82)
|
< 0.001
|
LVEF, %
|
60.5 ± 8.3
|
60.4 ± 9.3
|
54.7 ± 10.7
|
0.001
|
62.3 ± 9.0
|
61.3 ± 9.5
|
57.2 ± 12.8
|
0.042
|
Medication, n (%)
|
ACE inhibitors/ARBs
|
53 (53.5)
|
42 (56.0)
|
26 (56.5)
|
0.924
|
50 (37.9)
|
20 (33.3)
|
11 (39.3)
|
0.798
|
β blockers
|
41 (41.4)
|
30 (40.0)
|
20 (43.5)
|
0.931
|
51 (38.6)
|
25 (41.7)
|
15 (53.6)
|
0.345
|
Calcium channel blockers
|
30 (30.3)
|
23 (30.7)
|
12 (26.1)
|
0.845
|
41 (31.1)
|
13 (21.7)
|
8 (28.6)
|
0.406
|
Nitrates
|
57 (57.6)
|
41 (54.7)
|
24 (52.2)
|
0.819
|
59 (44.7)
|
32 (53.3)
|
16 (57.1)
|
0.339
|
Statins
|
69 (69.7)
|
59 (78.7)
|
36 (78.3)
|
0.328
|
77 (58.3)
|
33 (55.0)
|
12 (42.9)
|
0.325
|
Anti-diabetic therapy
|
58 (58.6)
|
60 (80.0)
|
40 (87.0)
|
< 0.001
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
–
|
Aortic blood pressure, mmHg
|
Systolic
|
150.2 ± 26.2
|
147.3 ± 23.4
|
141.2 ± 24.8
|
0.130
|
150.2 ± 29.2
|
147.0 ± 28.2
|
141.0 ± 17.9
|
0.260
|
Diastolic
|
77.1 ± 9.8
|
74.9 ± 9.4
|
73.5 ± 10.8
|
0.093
|
78.1 ± 13.2
|
75.9 ± 9.7
|
75.6 ± 11.5
|
0.388
|
Mean
|
101.5 ± 13.2
|
99.0 ± 11.8
|
96.1 ± 13.5
|
0.057
|
101.2 ± 14.7
|
101 ± 12.9
|
97.4 ± 7.7
|
0.407
|
Pd, mmHg
|
52.1 ± 9.4
|
39.6 ± 11.0
|
32.5 ± 10.2
|
< 0.001
|
53.6 ± 7.1
|
48.3 ± 8.6
|
35.6 ± 7.8
|
< 0.001
|
Collateral flow index
|
0.49 ± 0.09
|
0.36 ± 0.10
|
0.29 ± 0.09
|
< 0.001
|
0.51 ± 0.08
|
0.45 ± 0.08
|
0.35 ± 0.08
|
< 0.001
|